Conversely, serum PON1 activity was significantly enhanced in NAFLD mice (151.6% and 111%, respectively) following treatment with AT and RSV (p = 0.003 and 0.035, respectively; Figure 3B). The gene discussed is PON1; the disease is metabolic dysfunction-associated steatotic liver disease.